Fewer Proprietary Drug Names Rejected With FDA, Industry On Same Page
This article was originally published in The Tan Sheet
Executive Summary
After several false starts, FDA and the pharma industry appear to be on the same page about vetting potential brand names for new drugs. FDA’s rate of rejecting proposed brand names has dropped from 50% or higher when the decade began to about 25%, according to Office of Surveillance and Epidemiology data.
You may also be interested in...
OTC Umbrella Branding Soaked By Regulatory Storm In Draft Guidance – CHPA
The trade group recommends FDA write a separate proprietary name guidance for OTC drugs. FDA’s draft guidance also renders useless OTC manufacturers’ expertise in conducting tests to determine whether consumers safely self-select nonprescription drugs based on labeling, CHPA says in comments.
Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan
US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.
Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan
US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.